TherapeuticsMD reports FY2024 net loss narrowed to $2.3M; license revenue up 35%

TherapeuticsMD, Inc.

Net loss from continuing operations $(2.3)M, or $(0.20)/share, improved from $(7.7)M loss in 2023.
License revenue $1.8M, up 35.3% YoY, driven by changes in sales of Mayne licensed products.
Total operating expenses $6.5M, down 33.6% from $9.8M, due to cost cuts and transition to royalty model.
Cash and cash equivalents $5.1M as of December 31, 2024.
Company continues to evaluate strategic alternatives including M&A, sale of assets, or other transactions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.